Current place of monoamine oxidase inhibitors in the treatment of depression. - Wikidata - wikimedia - TriplyDB

Current place of monoamine oxidase inhibitors in the treatment of depression.

Current place of monoamine oxidase inhibitors in the treatment of depression.

http://www.wikidata.org/entity/Q34363276

about

Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches Pharmacology and Clinical Drug Candidates in Redox Medicine Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence A brief history of the development of antidepressant drugs: from monoamines to glutamate Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression Behavioural screening of zebrafish using neuroactive traditional Chinese medicine prescriptions and biological targets.The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment Therapeutic Effects of Phytochemicals and Medicinal Herbs on Depression.Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats.Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.Early life environmental and pharmacological stressors result in persistent dysregulations of the serotonergic system.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.Monoamine oxidase A and B substrates: probing the pathway for drug development.Monoamine oxidase: radiotracer chemistry and human studies.Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety.Zebrafish models of major depressive disorders.Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence.Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review.Toward a multiscale modeling framework for understanding serotonergic function.Differential protection of black-seed oil on econucleotidase, cholinesterases and aminergic catabolizing enzyme in haloperidol-induced neuronal damage of male rats.Regulatory Pathways of Monoamine Oxidase A during Social Stress.Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model.Monoamine oxidase inhibitory constituents of propolis: kinetics and mechanism of inhibition of recombinant human MAO-A and MAO-B.The antidepressant tranylcypromine alters cellular proliferation and migration in the adult goldfish brain.

P2860

Q26770334-54B90443-D28C-45EA-BBBF-AA8CDE492113 Q26785525-67429568-8D71-4E2D-86B6-15C1B8BAFD29 Q26999258-4BA0A978-F764-484E-962C-BBED2D7B110B Q27028050-CA1128C1-3FF2-492D-87EF-CFF95138C963 Q28069609-014ABFDC-47C0-4079-B23D-EDCA96425310 Q28084183-46307564-64B7-412D-9B2E-34A8A1BD5BFE Q30580754-59F05DA3-F32F-4136-9DB9-88127CD250E7 Q33593061-F6EE9629-91DF-4359-B42F-97FF00F183CF Q33630966-C9A05C3F-E4A5-429B-A11B-32FC2F6C0499 Q33936233-B32B3E23-9AA2-48D2-96BE-76C6B48B4CD1 Q34906855-BC899438-23C6-4753-B334-842556B2072B Q35541020-4CFFFBC8-5B3C-4755-937D-D103A8C4BEA2 Q35862776-D43F0D7F-E9E0-42FA-9EDA-AEB0FCB8742C Q36237385-A9095E3B-7C41-463B-96CE-7C2B6073249D Q36722925-3FD616BF-236F-4EBA-86A6-143D0708BBFA Q36983563-D47BA463-E6D8-41E2-99BA-9DF44B05BADC Q37158450-15322EF6-345A-4517-8288-C5D16D53F883 Q37279054-3096CA60-F297-427C-9EFF-2A6C8781FAE2 Q37552410-F1EA577B-037F-46B2-9897-8E548295B453 Q38217505-64BB7966-84D3-43A0-8530-9765FD0E5634 Q38354327-DF598EEC-E1E5-4253-A8C8-FC21C9AA3AB6 Q38367401-9617C4C5-7E5E-4930-B70E-EC67147484AC Q38603307-20306E66-45D2-45AB-A103-AD144378A6B1 Q38617975-582233F8-B603-4BF6-91D8-C2E017B137B9 Q38865983-C89C400A-AFDA-4B30-B7B0-92960BCD4D6D Q39048593-39CD2ACD-3B29-4458-BACF-89F9E80D3239 Q39247652-F9C98699-D6EC-4C53-AE0F-AFC8C17D088F Q42406412-79E3E808-34F9-49C6-A38D-6C8E54A6D104 Q47171927-F5CBDA88-B9A8-4AD5-8C84-E4A9EBFF819B Q47561695-89224E11-844D-42D2-BE00-AFC6742872FD Q48172504-1601065F-49A2-4D86-B1D8-D8DCEDC4FFB8 Q48296756-244B37E0-9A6B-40A0-B9D3-43814EAE836F

P2860

Current place of monoamine oxidase inhibitors in the treatment of depression.

http://www.wikidata.org/entity/Q34363276

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Current place of monoamine oxidase inhibitors in the treatment of depression.

@ast

Current place of monoamine oxidase inhibitors in the treatment of depression.

@en

Current place of monoamine oxidase inhibitors in the treatment of depression.

@nl

type

label

Current place of monoamine oxidase inhibitors in the treatment of depression.

@ast

Current place of monoamine oxidase inhibitors in the treatment of depression.

@en

Current place of monoamine oxidase inhibitors in the treatment of depression.

@nl

prefLabel

Current place of monoamine oxidase inhibitors in the treatment of depression.

@ast

Current place of monoamine oxidase inhibitors in the treatment of depression.

@en

Current place of monoamine oxidase inhibitors in the treatment of depression.

@nl

P1433

Q34363276-2ADB8C0A-271A-4F65-81A0-53154A7AB268

P1476

Q34363276-7D49D8AD-3483-4BDF-A583-7962DD21785F

P2093

Q34363276-2C60BCF7-A1C4-471F-B042-7B131B2BB094

Q34363276-899803D3-C9FA-43F5-8045-AB4CDE34E6B0

Q34363276-DE4054D1-FA64-471A-A1CC-9CD7EC7EA86A

P2860

Q34363276-02287150-BF72-4534-A51C-B71CED2BF425

Q34363276-16424FC5-1F03-4EA3-9C4D-AB9615006495

Q34363276-172C1845-1D27-4456-B235-C24E607016E9

Q34363276-1799D374-0021-42F6-8229-D29E878189D6

Q34363276-20891805-392F-4D06-99B1-F3BCB2C018EC

Q34363276-22AADA4A-D253-46CD-8F2B-2B47D023313E

Q34363276-2ECC1FCC-A348-4B1C-8416-C1AFF33941AC

Q34363276-30604E78-BAD3-4330-B21D-54DAB49BF528

Q34363276-38D78362-0719-4A27-824E-1AA07076ECB6

Q34363276-4C9AEF58-4997-4E1B-85CD-1A4C1381ABAE

P2888

Q34363276-721D8B07-6205-44A4-8C2B-7DDE05462476

P304

Q34363276-CE79E9D7-71EB-42D5-8C32-5032C1708CB3

P31

Q34363276-93F00528-8993-4F96-9372-4664EC91D59B

P356

Q34363276-4FEBA9A2-185C-4669-8B4B-53C020604244

P433

Q34363276-C7E4AE85-5AC4-411D-914E-8B5D6AAB1BCC

P478

Q34363276-B462EB1F-C7AC-44AD-B426-DB6527E45348

P577

Q34363276-BDF3971F-8953-4435-8CA9-4BDD7A785C2D

P698

Q34363276-8E445BD5-95A5-453C-8BD9-CE63EF924649

P356

S40263-013-0097-3

P1433

P1476

Current place of monoamine oxidase inhibitors in the treatment of depression.

@en

P2093

Kenneth I Shulman

http://www.w3.org/2001/XMLSchema#string

Nathan Herrmann

http://www.w3.org/2001/XMLSchema#string

Scott E Walker

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression

Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies

MAO inhibitors: risks, benefits, and lore

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.

Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase.

Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors.

Clinical pharmacology of MAO inhibitors: safety and future.

P2888

s40263-013-0097-3

P304

789-797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-013-0097-3

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23934742

http://www.w3.org/2001/XMLSchema#string